Review on drug repositioning of some FDA-approved drugs for treatment of cancer/microbial diseases.

Authors

Magda M F Ismail, Taghreed Z Shawer, Omneya M ElBakry, Eman A A Baumy, Sally I Eissa

Published in

RSC advances. Jul 03, 2026. Epub Jul 03, 2026.

Abstract

This approach drastically cuts development times and expenses by utilizing pre-existing safety and pharmacokinetic data. It works very well to fulfill unmet needs in infectious diseases, uncommon diseases, and cancer. Here, we provide an overview of FDA-approved medications that have been repurposed, covering biological features, modes of action, and synthetic processes.

PMID:
42405136
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.